Long-Term Results Favor Acalabrutinib Combo in MCL

Published Date: 19 Sep 2026

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Too Many Chest CTs for Incidental Lung Nodules?

2.

Major Shifts in Urothelial Cancer Care: Immunotherapy Redefines Standards

3.

Access to GLP-1 medications associated with a lower risk of colorectal cancer in people with type 2 diabetes: JAMA.

4.

Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.

5.

Breast Cancer Incidence Rises in Asian American Women


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot